Table Of Contents
1 Introduction 32
1.1 Overview Of Asia-Pacific Injectable Drug Delivery Market 32
1.2 Currency And Pricing 33
1.3 Limitation 33
1.4 Markets Covered 34
2 Market Segmentation 37
2.1 Markets Covered 37
2.2 Geographic Scope 38
2.3 Years Considered For The Study 39
2.4 Currency And Pricing 39
2.5 Research Methodology 40
2.6 Primary Interviews With Key Opinion Leaders 43
2.7 Secondary Sources 44
2.8 Assumptions 44
3 Market Overview 45
3.1 Drivers 47
3.1.1 Rising Cases Of Chronic Diseases 47
3.1.2 Rising Demand Of Self-Injection Devices 49
3.1.3 Growth Of Biologics Market 49
3.1.4 Technological Advancements And Innovations In Drug Delivery Market 50
3.2 Restraints 51
3.2.1 Needlestick Injuries And Infections 51
3.2.2 High Cost Of Development 52
3.2.3 Strict Regulatory Framework 53
3.3 Opportunity 54
3.3.1 Increasing Demand For Generic And Biosimilar Drugs 54
3.3.1.1 Generics 54
3.3.1.2 Biosimilars 54
3.3.2 Increasing Demand For Contraceptive Injectables 55
3.3.3 Increasing Demand For Self-Administration Of Drugs 56
3.4 Challenges 57
3.4.1 Alternative Route Of Drug Administration 57
3.4.2 Product Recall 58
3.4.3 Stability Of Products 58
3.4.4 Sterility Of Injections 59
4 Executive Summary 60
5 Premium Insights 62
6 Asia-Pacific Injectable Drug Delivery Market, By Type 65
6.1 Overview 66
6.2 Injectable Drug Delivery Devices 67
6.2.1 Conventional Injection Devices 68
6.2.1.1 Conventional Injection Devices, By Material 70
6.2.1.1.1 Glass 70
6.2.1.1.2 Plastic 70
6.2.1.2 Conventional Injection Devices, By Product 71
6.2.1.2.1 Fillable Syringes 71
6.2.1.2.2 Prefilled Syringes 72
6.2.1.3 Conventional Injection Devices, By Usability 73
6.2.1.3.1 Reusable Syringes 73
6.2.1.3.2 Disposable Syringes 73
6.2.2 Self Injection Devices 74
6.2.2.1 Needle Free Injectors (Nfi) 75
6.2.2.2 Needle Free Injectors, By Product 76
6.2.2.2.1 Fillable Needle-Free Injectors 76
6.2.2.2.2 Prefilled Needle-Free Injectors 76
6.2.2.3 Needle Free Injectors, By Technology 77
6.2.2.3.1 Jet Based Needle Free Injectors; 77
6.2.2.3.2 Spring Based Needle Free Injectors; 78
6.2.2.3.3 Laser Based Needle Free Injectors; 78
6.2.2.3.4 Vibration Based Needle Free Injectors; 78
6.2.2.4 Needle Free Injectors, By Usability 79
6.2.2.4.1 Reusable Needle-Free Injectors 79
6.2.2.4.2 Disposable Needle-Free Injectors 79
6.2.2.5 Auto Injectors 80
6.2.2.6 Auto Injectors, By Product 81
6.2.2.6.1 Fillable Auto Injectors 81
6.2.2.6.2 Pre-Filled Autoinjectors 81
6.2.2.7 Auto Injectors, By Technology 82
6.2.2.7.1 Automated Auto Injectors 82
6.2.2.7.2 Manual Auto Injectors 82
6.2.2.8 Auto Injectors, By Design 84
6.2.2.8.1 Standardized Auto Injectors 84
6.2.2.8.2 Automated Autoinjectors 84
6.2.2.9 Auto Injectors, By Usability 85
6.2.2.9.1 Reusable Autoinjectors 85
6.2.2.9.2 Disposable Autoinjectors 85
6.2.2.10 Pen Injectors 86
6.2.2.11 Pen Injectors, By Product 86
6.2.2.11.1 Single Chambered Pen Injectors 86
6.2.2.11.2 Dual Chambered Pen Injectors 87
6.2.2.12 Pen Injectors, By Design 87
6.2.2.12.1 Standard Pen Injectors 87
6.2.2.12.2 Customized Pen Injectors 88
6.2.2.13 Pen Injectors, By Usability 88
6.2.2.13.1 Reusable Pen Injectors 88
6.2.2.13.2 Disposable Pen Injectors 89
6.2.2.14 Wearable Injectors 89
6.2.2.14.1 Other Devices 90
6.3 Injectable Drug Delivery Formulation 91
6.3.1 Conventional Drug Delivery Formulations 92
6.3.1.1 Solutions 92
6.3.1.2 Reconstituted/Lyophilized Formulations 92
6.3.1.3 Suspensions 93
6.3.1.4 Emulsions 94
6.3.2 Novel Drug Delivery Formulations 96
6.3.2.1 Colloidal Dispersions 97
6.3.2.1.1 Niosomes 97
6.3.2.1.2 Liposomes 98
6.3.2.1.3 Polymeric Mixed Micelles 99
6.3.2.1.4 Nanoparticles 100
6.3.2.1.5 Nanosuspensions 100
6.3.2.1.6 Nanoemulsions/Microemulsions 101
6.3.2.1.7 Solid Lipid Nanoparticles 102
6.3.2.2 Microparticles 103
6.3.2.2.1 Microspheres 103
6.3.2.2.2 Microcapsules 104
6.3.2.3 Long Acting Injection Formulation 105
7 Asia-Pacific Injectable Drug Delivery Market, By Application 107
7.1 Overview 108
7.2 Asia-Pacific Injectable Drug Delivery Market, By Application 109
7.3 Hormonal Disorders 110
7.3.1 Injectable Drugs For Diabetes 110
7.3.2 Injectable Drugs For Anemia 111
7.3.3 Injectable Drugs For Reproductive Health Disease 113
7.3.4 Injectable Drugs For Antithrombotic/Thrombolytic Therapy 114
7.3.5 Injectable Drugs For Osteoporosis 114
7.3.6 Injectable Drugs For Growth Hormone Disorders (Ghd) 115
7.4 Oncology 117
7.5 Autoimmune Diseases 119
7.5.1 Injectable Drugs For Rheumatoid Arthritis 119
7.5.2 Injectable Drugs For Multiple Sclerosis 120
7.5.3 Injectable Drugs For Crohn?S Diseases 121
7.5.4 Injectable Drugs For Psoriasis 122
7.5.5 Injectable Drugs For Other Autoimmune Diseases 123
7.6 Orphan Disease 124
7.7 Other Applications 126
7.7.1 Injectable Drugs For Pain Management 126
7.7.2 Injectable Drugs For Allergy Treatment 127
7.7.3 Injectable Drugs For Aesthetic Treatments 128
7.7.4 Injectable Drugs For Hepatitis C 129
7.7.5 Injectable Drugs For Hemophilia 130
8 Asia-Pacific Injectable Drug Delivery Market, By Usage Pattern 132
8.1 Overview 133
8.2 Curative Care 134
8.3 Immunizations 135
8.4 Other Usage Pattern 136
9 Asia-Pacific Injectable Drug Delivery Market, By Mode Of Administration 137
9.1 Overview 138
9.2 Skin 139
9.3 Circulatory/ Muskoskeletal 139
9.4 Organs 140
9.5 Central Nervous System 141
10 Asia-Pacific Injectable Drug Delivery Market, By End User 142
10.1 Overview 143
10.2 Hospitals And Clinics 145
10.3 Home Healthcare Settings 145
10.4 Research Laboratories 145
10.5 Pharmaceutical And Biotechnological Companies 146
10.6 Other End Users 147
11 Asia-Pacific Injectable Drug Delivery Market, By Distribution Channel 148
11.1 Overview 149
11.1.1 Hospital Pharmacy 150
11.1.2 Pharmacy Stores 150
11.1.3 Direct Tender 150
11.1.4 Online Pharmacy 150
12 Asia-Pacific Injectable Drug Dilivery Market By Geography 152
12.1 Asia-Pacific 152
12.1.1 Japan Injectable Drug Delivery Market 171
12.1.2 China Injectable Drug Delivery Market 187
12.1.3 India Injectable Drug Delivery Market 202
12.1.4 South Korea Injectable Drug Delivery Market 217
12.1.5 Australia Injectable Drug Delivery Market 232
12.1.6 Thailand Injectable Drug Delivery Market 247
12.1.7 Malaysia Injectable Drug Delivery Market 263
12.1.8 Singapore Injectable Drug Delivery Market 278
12.1.9 Indonesia Injectable Drug Delivery Market 293
12.1.10 Phillippines Injectable Drug Delivery Market 308
12.1.11 Rest Of Asia-Pacific Injectable Drug Delivery Market 323
13 Asia-Pacific Injectable Drug Delivery Market, Company Share 324
13.1 Company Share Analysis; Asia-Pacific 324
14 Company Profiles 325
14.1 Becton, Dickinson And Company 325
14.1.1 Company Overview 325
14.1.1.1 Drivers Explained 326
14.1.1.2 Weaknesses Explained 326
14.1.1.3 Oppurtunities Explained 327
14.1.1.4 Threats Explained 327
14.1.2 Product Portfolio 328
14.1.3 Recent Developments 329
14.2 Pfizer 330
14.2.1 Company Overview 330
14.2.1.1 Drivers Explained 331
14.2.1.2 Weaknesses Explained 332
14.2.1.3 Oppurtunities Explained 332
14.2.1.4 Threats Explained 333
14.2.2 Product Portfolio 334
14.2.3 Recent Developments 335
14.3 Baxter International 336
14.3.1 Company Overview 336
14.3.1.1 Drivers Explained 337
14.3.1.2 Weaknesses Explained 338
14.3.1.3 Oppurtunities Explained 338
14.3.1.4 Threats Explained 339
14.3.2 Product Portfolio 340
14.3.3 Recent Developments 341
14.4 Gerresheimer Ag 342
14.4.1 Company Overview 342
14.4.2 Product Portfolio 343
14.4.3 Recent Developments 343
14.5 Schott Ag Inc. 344
14.5.1 Company Overview 344
14.5.2 Product Portfolio 345
14.5.3 Recent Developments 345
14.6 Alkermes Inc. 346
14.6.1 Company Overview 346
14.6.2 Product Portfolio 347
14.6.3 Recent Developments 347
14.7 Antares Pharma 348
14.7.1 Company Overview 348
14.7.2 Product Portfolio 349
14.7.3 Recent Developments 349
14.8 Bespak (Subsidiary Of Consort Medical Company) 351
14.8.1 Company Overview 351
14.8.2 Product Portfolio 352
14.8.3 Recent Developments 352
14.9 Elcam Medical 353
14.9.1 Company Overview 353
14.9.2 Product Portfolio 353
14.9.3 Recent Developments 353
14.10 Eli Lilly And Company 354
14.10.1 Company Overview 354
14.10.1.1 Drivers Explained 355
14.10.1.2 Weaknesses Explained 356
14.10.1.3 Oppurtunities Explained 356
14.10.1.4 Threats Explained 357
14.10.2 Product Portfolio 358
14.10.3 Recent Developments 359
14.11 Haselmeier 360
14.11.1 Company Overview 360
14.11.2 Product Portfolio 360
14.11.3 Recent Developments 361
14.12 Mylan N.V. 362
14.12.1 Company Overview 362
14.12.2 Product Portfolio 362
14.12.3 Recent Developments 363
14.13 Novo Nordisk 364
14.13.1 Company Overview 364
14.13.2 Product Portfolio 365
14.13.3 Recent Developments 366
14.14 Owen Mumford Ltd 367
14.14.1 Company Overview 367
14.14.2 Product Portfolio 368
14.14.3 Recent Developments 368
14.15 Sandoz International Gmbh 369
14.15.1 Company Overview 369
14.15.2 Product Portfolio 370
14.15.3 Recent Developments 370
14.16 Sanofi 371
14.16.1 Company Overview 371
14.16.2 Product Portfolio 372
14.16.3 Recent Developments 373
14.17 Terumo Corporation 374
14.17.1 Company Overview 374
14.17.2 Product Portfolio 375
14.17.3 Recent Developments 375
14.18 Teva Pharmaceutical 377
14.18.1 Company Overview 377
14.18.1.1 Drivers Explained 378
14.18.1.2 Weaknesses Explained 378
14.18.1.3 Oppurtunities Explained 379
14.18.1.4 Threats Explained 380
14.18.2 Product Portfolio 381
14.18.3 Recent Developments 382
14.19 West Pharmaceutical Services, Inc 383
14.19.1 Company Overview 383
14.19.2 Product Portfolio 384
14.19.3 Recent Developments 385
14.20 Ypsomed Holding Ag 386
14.20.1 Company Overview 386
14.20.2 Product Portfolio 387
14.20.3 Recent Developments 387
15 Related Reports 388
?